经济合作伙伴
Auriga Partnershttp://www.aurigapartners.comAuriga Partners is an independent technological venture capital company, based in Paris. It invests shareholders' funds in the fields of information technology and life sciences. The company invests in innovative projects marked by high potential, either in their creation or at an early development stage, in Europe, North America and Israel. Auriga Partners now manages three funds, a total of more than 198 million euros. Auriga Partners provides the companies in its portfolio with advice and know-how in structuring managerial teams, internal organization and the creation of strategic partnerships.
|
|
Canon Inc.http://www.canon.com/index.htmlCanon Inc., headquartered in Tokyo, Japan is a leader in the fields of professional and consumer imaging equipment and information systems. Originally established in 1937 as Precision Optical Industry, Co., Ltd., a camera manufacturer, Canon has successfully diversified and globalized its operations to become a worldwide industry leader in professional and consumer imaging systems and solutions. Canon has set its sights on the future to provide society with new forms of value, promoting research and development in such areas as medical imaging employing optical-sensor and image- processing technologies.
|
|
CDC entrepriseswww.cdcentreprises.frCDC Entreprises is a management company authorized by France’s financial market regulator, the AMF, and a wholly-owned subsidiary of the Caisse des Dépôts. CDC Entreprises manages the group’s public interest activities, including the FSI (the French Strategic Fund), in the field of private equity for SMEs and other public and private institutions investing in small and medium-size French Businesses. It makes direct and indirect investments in companies, on a national or regional level, ranging from technology seed funding to small company transmissions. CDC Entreprises covers SMEs’ entire financing chain. It takes more risk than the traditional players, positioning itself much more strongly in activities such as the provision of seed money and venture capital, and targeted areas such as biotechnology. It takes stakes in SMEs’ capital up to a maximum of €15 million for any one company.
|
|
Omnes Capitalwww.omnescapital.com
Omnes Capital (formerly Crédit Agricole Private Equity) is a major player in private equity, with a commitment to financing SMEs.
|
|
Edmond de Rothschild Investment Partnershttp://www.edrip.frParis-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It has currently EUR 650M under management which is being invested primarily as life sciences venture capital and growth capital. Its Life Science Team of six professionals brings together over 30 years of experience in the Life Science industry and more than 50 years of private equity and venture capital experience. The team has approximately EUR 300 M under management after having recently raised EUR 150 M through BioDiscovery III. Edmond de Rothschild Investment Partners is an independently managed affiliate of La Compagnie Financière Edmond de Rothschild Banque.
|
|
IXO Private Equityhttp://www.icso.frIXO Private Equity is a private equity firm managing FCPR and FIP and advising IRDI, en evergreen fund. IXO invests in Venture Capital, LBO and Capital Development. Founded 30 years ago and located in Toulouse, IXO is the most important French regional independent actor in private equity managing €300M. It invests from €500K to €10M by target company in the West and South of France.
|
|
Merieux Développementhttp://www.merieux-developpement.comMérieux Développement is the healthcare investment company of Institut Mérieux, a French industrial holding company dedicated to healthcare, which currently employs nearly 10,000 people worldwide. Institut Mérieux has majority ownership of bioMérieux (Euronext Paris, BIM), Silliker, Transgene and ABL Inc. Mérieux Développement intends to invest up to €70 million as minority shareholder from 2010 to 2013 in the field of life science on a global basis, working alongside entrepreneurs and innovative companies whose products and services can bring genuine advances to the health of patients and consumers worldwide.
|
|
NBGI Ventureshttp://www.nbgiventures.comNBGI Ventures manages the EUR 60m NBG Technology LP, which invests in promising technology-centric companies in Europe, including Greece. The NBG Technology LP is an independent fund, based in the UK and backed by three prominent financial institutions, including the European Investment Fund (EIF).
Operating from its offices in London and Athens, NBGI Ventures is managed by a dedicated team of professionals with substantial experience in both the technology and financial sectors.
|
|
Wellington Partnershttp://www.wellington-partners.comWellington Partners has been one of the most successful pan-European venture capital firms for more than 10 years.With funds totaling € 800 million and offices in London, Munich, Palo Alto and Zurich, Wellington Partners invests in companies throughout Europe that have the potential for becoming global leaders.Wellington Partners' investment areas include Digital Media, Information Technology, Cleantech and Life Science. |
|
